CD276 and glioblastoma: Therefore, B7-H3 represents a promising TAA and different clinical trials targeting B7-H3 are ongoing in adult patients affected by glioblastomas or CNS metastasis, and, more recently, in pediatric patients with recurrent or refractory gliomas and medulloblastomas.